Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature

• Published in: Journal of clinical pharmacy and therapeutics Vol. 42; no. 2; pp. 234 - 236
• Main Authors: Cortes, X., Borrás‐Blasco, J., Antequera, B., Fernandez‐Martinez, S., Casterá, E., Martin, S., Molés, J. R.
• Format: Journal Article
• Language: English
• Published: England Hindawi Limited 01-04-2017
• Subjects: adalimumab; Adult; biologics; Crohn Disease - drug therapy; Crohn's disease; Female; Humans; infliximab; Pregnancy; Pregnancy Complications - drug therapy; ustekinumab; Ustekinumab - therapeutic use; Crohn's disease; ustekinumab; biologics; infliximab; adalimumab; pregnancy
• ISSN: 0269-4727; 1365-2710
• DOI: 10.1111/jcpt.12492

Summary
What is known and objectives
The safety of continued ustekinumab (UST) therapy during pregnancy remains unclear in patients with Crohn's disease (CD). There are no meta‐analysis reports of exposure to UST during pregnancy. The objective was to describe a case of a pregnant patient with CD who was successfully treated with UST maintenance therapy throughout the pregnancy and delivered a baby boy without any congenital malformations, neurological abnormalities or birth defects.
Case summary
A 37‐year‐old patient with CD treated with UST became pregnant. She had been receiving UST for 8 months at the time. After discussion with the patient and the obstetric team, the UST therapy was continued. The result of treatment was an uneventful pregnancy with delivery, at term, of a healthy boy and the maintenance of clinical, biological and endoscopic remission of CD during and after pregnancy.
What is new and conclusion
To our knowledge, this is the first reported use of continued UST therapy for CD throughout a pregnancy. The result of treatment was an uncomplicated pregnancy with the mother giving birth to a healthy boy at term and the maintenance of clinical biological and endoscopic remission of CD during and after pregnancy.